1. Sweden Stocks

  2. •

    Health technology

  3. •

    Biotechnology
AlzeCure Pharma AB

AlzeCure Pharma AB

6.58
SEK
-0.34
(-4.91%)
0.24EPS
15.86P/E
444.72MMarket Cap
Nov 11Next Earn
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
0.77
Basic EPS, GAAP
-0.42
-1.12
-0.95
-1.34
-1.52
-0.87
-0.44
-0.38
-0.42
0.24
Free Cash Flow per Basic Share
-0.34
-1.14
-0.97
-1.32
-1.38
-1.54
0.04
-0.37
-0.3
-0.42
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.97
4.37
3.41
2.08
0.62
0.87
0.28
0.25
0.25
0.8
Tangible Book Value per Share
0.97
4.37
3.41
2.08
0.62
0.87
0.28
0.25
0.25
0.8
Basic Weighted Avg Shares
26
32
53
53
51
65
84
93
115
126
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
97
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
31.28
Depreciation Expense
- -
- -
- -
- -
1
1
- -
1
1
1
Net Income, GAAP
-11
-36
-51
-71
-78
-56
-37
-35
-48
31
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
31.56
Working Capital
52
233
180
109
32
17
22
24
31
90
LT Debt
- -
- -
- -
- -
- -
- -
5
4
3
2
Total Equity
52
233
182
111
33
60
24
26
33
91
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-25.25
-24.5
-48.75
-108.23
-120.35
-88.22
-141.83
-161.56
62.85

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
3
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
131
131
115
Market Capitalization
230
193
445

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
55
37
119
Cash, Cash Equivalents & STI
50
33
13
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
27
29
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-2.31%
26.27%
Free Cash Flow
- -
-256.8%
0.7%
Net Income, GAAP
- -
-4.54%
34.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
97
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.12
-0.1
-0.07
-0.09
-0.38
2025
-0.1
-0.11
-0.08
-0.14
-0.42
2026
-0.17
0.7
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Martin Jönsson
Full Time Employees
10
Sector
Health technology
Industry
Biotechnology
Address
Hälsovägen 7 Huddinge AB Sweden 141 57
IPO Date
Nov 28, 2018
Website
alzecurepharma.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
AlzeCure Pharma AB (publ) (ALZCUR.ST) is a Sweden-based pharmaceutical company founded in 2016 and headquartered in Huddinge that focuses on developing innovative small-molecule drug candidates for central nervous system disorders, primarily Alzheimer's disease and severe pain conditions; its lead platforms include NeuroRestore for symptomatic cognitive treatments, Alzstatin for disease-modifying Alzheimer's therapies, and Painless for non-opioid pain relief. Core products encompass NeuroRestore ACD856, a positive allosteric modulator of Trk receptors in Phase II clinical development targeting Alzheimer's disease, cognitive dysfunction from Parkinson's disease, traumatic brain injury, sleep disorders and depression; NeuroRestore ACD857 in research for Alzheimer's; Alzstatin ACD680, a gamma-secretase modulator in preclinical stage to reduce amyloid-beta-42 plaques; Painless ACD440, a TRPV1 antagonist gel that completed Phase IIa with positive efficacy in neuropathic pain and received U.S. FDA Orphan Drug Designation for erythromelalgia in July 2025; and Painless ACD137 (TrkA-NAM), a preclinical candidate demonstrating analgesic and anti-inflammatory effects in osteoarthritis pain models. The company operates primarily in Sweden with a diversified pipeline addressing unmet needs in neurodegenerative diseases and chronic pain for patient populations including those unresponsive to current therapies. Recent developments include a EUR 2.5 million grant from the European Innovation Council in February 2025 to support Phase IIa trials of ACD856, including higher dosing evaluations; a rights issue in July 2025 oversubscribed by 212% raising SEK 58.5 million; Orphan Drug Designation for ACD440 in erythromelalgia with positive FDA guidance for Phase IIb/III; new preclinical data for ACD137 presented at NeuPSIG 2025; appointment of Cecilia Wadell as Head of Development in August 2025; and a December 2025 payment receipt for the EIC grant.